Welcome to Anne Hege Aamodt's project group

Our scientific interest research is acute stroke treatment and diagnostic workup in acute ischemic stroke and the relation between stroke and atrial fibrillation.

Anne Hege AamodtProject group leader
Anne Hege Aamodt
Project group leader
The Research Group’s Objectives and Strategy

  1. Acute revascularization therapy: Our research focuses on endovascular intervention, which is centralized in the South-Eastern Norway Regional Health Authority to Oslo University Hospital. In cooperation with the neuroradiologist we are doing prospective studies to develop this treatment option further and explore the clinical outcome of endovascular intervention in acute ischemic stroke patients in relation to logistics, clinical and radiological selection. We are also doing analyses of the costs, quality of life and functional level in patients treated with endovascular intervention. In cooperation with the prehospital services we are studying the effect of prehospital selection.

  2. Cryptogenic stroke: We are leading an international prospective multi-center study with long term rhythm monitoring and biomarkers to explore the impact of atrial fibrillation.

  3. Brain health in atrial fibrillation: Patients with atrial fibrillation have an increased risk of stroke, cognitive decline and premature death. Even in the absence of clinical stroke, people with incident AF are likely to reach thresholds of cognitive impairment or dementia at earlier ages than people with no history of AF. We are exploring the impact of inflammation and fibrosis on the risk of stroke, cognitive impairment and AF recurrence in patients with atrial fibrillation in a prospective study that uses advanced technology with 18F-FDG-PET, MRI and biomarkers.
    The European Cerebrovascular Research Infrastructure: Anne Hege Aamodt is the manager of a cerebrovascular research infrastructure with a separate biobank and several ongoing multi-center studies and collaborators in all health regions in Norway and Scandinavia.

Contact information: Anne Hege Aamodt

Meeting in the stroke research group at the Division of Clinical Neuroscience and the Divsion of Medicine: From left Gudrun Høie, Mona-Elisabeth Revheim, Anna Lambert, Kristine Stø, Hege Ihle-Hansen, Hilde Slaatta, Erik Prestgaard, Georgios Vlachos, Karianne Larsen, Dan Atar, Eivind Berge and Erik Eriksen.

News and events:

5th European Stroke Organisation Conference (EOC), Milan, 22-24 May 2019. ESOC The European Stroke Organisation Conference

The NOR-FIB study is presented at two sessions during ESOC with new data from the biomarker study and updated data on the inclusion of participants. Many of the investigators participated at the Investigator meeting during the first day of the congress.

Click to enlarge image


EAN Investigator Award 2018 to Anne Hege Aamodt

Anne Hege Aamodt, manager of ECRI, was during the EAN conference given the "EAN Investigator Award 2018" for her presentasjonen entitled "Effect and safety of tenecteplase in stroke patients with atrial fibrillation".

Investigator Award Winners 2018

EAN congress Lisbon 2018 homepage

June 16-19 2018 The 4th Congress of the European Academy of Neurology in Lisbon

At the 4th Congress of the European Academy of Neurology in Lisbon (EAN 2018) three studies were presented from the group. 
Gry Grønli had an ePresentation from a single centre study on cerebral venous thrombosis from Oslo University Hospital. PhD student Anna T. Lambert presented data from the pilot study of NOR-FIB at an oral session and Anne Hege Aamodt presented data with atrial fibrillation in NOR-TEST study.
Both NOR-FIB and NOR-TEST were selected for the highlight session of the congress. Next year the congress is in Oslo and a lot of preparation for the congress was done in Lisbon both by the local organising committee and by the Norwegian Neurological Association which Anne Hege Aamodt is the president of. You can find more information on the EAN2018 here: https://www.ean.org/oslo2019/

May 16-18 2018 European Stroke Organisation Congress in Gothenburg

Anne Hege Aamodt was invited speaker at the European Stroke Organisation Congress in Gothenburg in May to talk about treatment in Central Retinal Artery Occlusion and presented at new planned international randomised controlled trial with tenecteplase - the TEN-CRAOS Study.
The NOR-FIB study was also presented at ESOC by PhD student Anna T. Lambert and there was an Investigator meeting with participants from all Scandinavian countries.